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Abstract 
INTRODUCTION: 
Cerebrospinal fluid (CSF) biomarkers have the potential to improve the diagnostic 
accuracy of Alzheimer’s disease. A lack of harmonized pre-analytical CSF-handling 
protocols accounts for a large proportion of observed variation and limits between-
study comparison of CSF biomarker concentrations. 
METHODS: 
This systematic review summarizes the current literature on the influence of different 
pre-analytical variables on CSF biomarker concentration. We evaluated the evidence 
for three core CSF biomarkers: β-Amyloid(1–42), total tau and phosphorylated tau.  
RESULTS: 
This review highlights where previous literature agrees on the influence of certain 
variables on CSF biomarkers, and where there is a lack of consensus, or little 
evidence available.   
DISCUSSION: 
A unified CSF handling protocol is recommended to reduce pre-analytical variability 
and facilitate comparison of CSF biomarkers across studies and laboratories.   
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Research in context 
Systematic review: The PubMed and Cochrane databases were searched between 
1995 and March 2017 with specific search terms to identify studies that analyzed the 
effect of pre-analytical variables on cerebrospinal fluid (CSF) biomarkers of 
Alzheimer’s disease (AD). Relevant publications were identified, screened, and 
assessed. A total of 49 publications were analysed for the influence of pre-analytical 
variables and the results are discussed. We also summarize the variations between 
currently used CSF handling protocols. 
Interpretation: This review highlights the consensus in the field on the influence of 
different pre-analytical variables. It also indicates where there is a lack of consensus 
or a need for further research.  
Future directions: We recommend developing a unified CSF handling protocol; this 
could reduce the impact of pre-analytical variables on biomarker measurement. This 
in turn could improve the diagnostic accuracy for AD and enhance clinical trial 
recruitment.  
 
Highlights 
 CSF biomarkers of Alzheimer’s disease are influenced by pre-analytical 
variables. 
 Inconsistencies in published evidence on each variable’s effect. 
 A unified protocol may reduce CSF biomarker variability and improve 
diagnosis. 
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1. Introduction 
Alzheimer’s disease (AD) is thought to be a continuum with three main stages: 
preclinical (cognitively unimpaired), prodromal (with mild cognitive symptoms), and 
dementia (more advanced clinical symptoms) [1]. Disease-modifying treatments in 
development targeted at AD will likely have greatest clinical benefit early in the AD 
continuum, before neuronal damage is widespread [2,3]. It is challenging to 
definitively diagnose early AD using clinical criteria alone [1]; however, biomarkers 
can detect changes in underlying neuropathology when only mild cognitive 
symptoms are present [4–7], or even at preclinical stages [8–12].  
1.1 The potential impact of biomarkers in AD diagnosis and research 
A biomarker is an objective measure of a biological or pathological process that can 
be used to monitor normal physiological processes, or evaluate disease risk or 
prognosis, to guide clinical diagnosis or to monitor therapeutic interventions [13]. 
Several physiological changes related to the pathogenesis of AD (such as neuritic 
plaques, tangles, and synapse loss) have been well documented. These are 
accompanied by changes in the levels of some molecules, both in the brain and 
cerebrospinal fluid (CSF), several of which have been suggested as potential 
biomarkers in the field of AD for specific applications (e.g., diagnosis, treatment 
follow-up) [14]. 
Patients with AD have a characteristic profile of altered concentrations of three CSF 
protein biomarkers: β-Amyloid (Aβ) (1–42), total tau (tTau), and phosphorylated tau 
(pTau) [15–17]. While these biomarkers may be individually affected by non-AD-
related pathologies, for example Aβ(1–42) in subcortical vascular dementia [18], the 
combination of the three core biomarker changes is known as the AD ‘signature’ or 
‘profile’ [4,5,19–22].  
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Aβ(1–42) is the main component of amyloid plaques associated with AD [23–25]. 
Currently, the only FDA-approved method to detect Aβ deposits within the brain is β-
amyloid positron emission tomography (PET) [26]. However, several commercially 
available assays for measuring Aβ(1–42) (and other core AD biomarkers) in CSF are 
approved for diagnostic use in the European Union [27–29]. In addition, ~10% of 
cognitively normal elderly individuals have biomarker evidence of amyloidosis but no 
cognitive symptoms [30]. Low CSF Aβ(1–42) could be an early indicator of preclinical 
AD before amyloid deposition rises to levels visible by PET imaging [31]. 
Brain amyloid pathology is correlated with abnormally low levels of Aβ(1–42) in the 
CSF [2,32–36]. There is high concordance of CSF Aβ(1–42) with β-amyloid PET 
status in both AD dementia and prodromal AD [4]. Concordance is further improved 
by using the ratio of CSF Aβ(1–42)/(1–40) , CSF pTau/Aβ(1–42) or CSF tTau/Aβ(1–
42) [16,18,37–40]. Altered levels in the concentration ratio of CSF Aβ(1–42) and 
Aβ(1–40) are observed in subjects influenced by the apolipoprotein E (APOE) 4 
allele [41], a strong genetic risk factor for AD [42].  
CSF tTau is increased following neuronal injury or degeneration and is associated 
with cognitive decline [43,44]. An increase in CSF tTau concentration is 
characteristic of neurodegenerative disorders such as AD [45], but is also found in 
acute neuronal injury, for example, ischaemic stroke [46], other tauopathies (e.g., 
corticobasal syndrome [47]), and very high concentrations are found in disorders 
with rapid neuronal degeneration, for example Creutzfeldt-Jakob disease (CJD) [48].  
Hyperphosphorylated tau is an important component of neurofibrillary tangles, which 
are a pathologic hallmark of AD [2,14,49]. High CSF pTau correlated with cortical 
tangle pathology in some studies [50,51], with the exception of Engelborghs, et al. 
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(2007) [52], while high levels of CSF pTau were found in AD patients (up to 3.4-fold 
higher than healthy controls) [53]. Studies have found that CSF pTau181P correlated 
with the amount of cortical amyloid measured via PET imaging [16] or CSF Aβ(1–
42)/(1–40) ratio [41]. The inclusion of pTau as a biomarker for AD together with 
Aβ(1–42) and tTau can help differentiate AD from normal ageing and difficult 
diagnoses (e.g., Parkinson’s disease, CJD, some forms of non-AD dementia), and 
improve diagnostic performance [54,55]. CSF pTau181P concentration was found to 
be the most statistically significant single variable of the three for discrimination 
between AD and dementia with Lewy bodies in one study [54]. While pTau181P is the 
most studied form, different phosphorylated epitopes, detected using different 
antibody combinations, may also result in a better separation of AD from non-AD 
dementia [56,57]. 
Research guidelines from the National Institute on Aging and the Alzheimer’s 
Association (NIA-AA; [58,59]) and International Working Group (IWG-2; [60]) 
recommend including core biomarkers in AD diagnostic assessment, while the 
European Academy of Neurology recommends CSF biomarker assessment to aid 
AD differentiation [61]. As well as having diagnostic potential, changes in the core 
AD biomarkers precede cognitive changes and predict clinical progression in 
patients with mild cognitive impairment (MCI) [5,7,17,62,63], and effectively stratify 
patients for their risk of developing AD dementia [5,7,20,21,39,64]. Promisingly, 
these biomarkers also detect pathological changes associated with preclinical AD in 
cognitively healthy elderly individuals [12,40,65,66], and can enhance both 
differential diagnosis and prognostic stratification within AD populations.  
Accurate, consistent, and reliable biomarker measurement remains a goal for 
researchers and clinicians alike, but requires consensus to establish universal cut-off 
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values. However, the significant variability documented in CSF biomarker 
measurements across research and clinical studies [2,67–69] has hampered these 
efforts. The translation of cut-off values between clinical sites and studies has been 
investigated [64,70] but can lead to patient misclassification, which in turn could 
influence clinical decision-making or clinical trial eligibility. 
1.2 Variables affecting CSF biomarker concentration 
CSF biomarker concentration can be affected by clinical, analytical, and pre-
analytical variables [71–73]. Clinical variables (besides AD and non-AD pathology) 
include age and APOE genotype [30]. Analytical procedures are related to the assay 
itself, for example, differences in technician skills and training, operating procedures, 
assay manufacturing or batch-to-batch variations in kits [74]. Considerable work has 
been done to standardize CSF biomarker measurement across different assays and 
laboratories. Notable efforts include: 1) the development of certified reference 
materials for the CSF biomarkers, currently underway within the International 
Federation of Clinical Chemistry Working Group for CSF proteins [75], 2) the 
introduction of reference measurement procedures (RMPs) based on liquid 
chromatography tandem mass spectrometry for CSF Aβ(1–42) quantification, which 
were recently formally certified by the Joint Committee for Traceability in Laboratory 
Medicine (C11RMP9 and C12RMP1, respectively) [76,77], and 3) the establishment 
of quality control programs for monitoring between-laboratory and between-batch 
variability of commercially available immunoassays [28,72,78–82].  
Pre-analytical variables include CSF sampling materials and methodology, CSF 
handling, and storage procedures (see [71,80] for reviews). Following notable 
improvements in analytical methods, recent studies have revealed that pre-analytical 
factors account for a considerable proportion of the total variability observed in 
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biomarker concentrations [71,83]. Thus, there is a growing view that standardization 
of selected pre-analytical factors might well significantly reduce this variability, 
improve biomarker diagnostic accuracy and encourage greater inclusion of CSF 
biomarker testing in both clinical research and routine clinical practice.  
1.3 Rationale for this systematic review 
Standardization of key analytical issues is increasingly being embraced by the AD 
community. In contrast, clinics and diagnostic laboratories have commonly 
developed their own site-specific protocols for the pre-analytical handling of CSF 
[14,80]. While some centres have published their protocols, the majority follow a 
small number of published protocols or recommendations, while a variety of 
adjustments to these protocols also have been published [35,71,80,84–87]. In 
addition, many unpublished adjustments to pre-analytical protocols have been 
adopted (Fagan A, personal observation). Where differences in pre-analytical 
procedures exist, direct comparison of CSF biomarker data between groups is 
difficult or biased, albeit possible [88]. As new studies are published, there is a need 
to update protocols and work towards their subsequent global implementation.  
2. Aim  
This review has two aims: 1) to compare current pre-analytical recommendations 
and protocols for handling CSF samples prior to measurements of the core AD 
biomarkers of Aβ(1–42), pTau and tTau and 2) to summarize the effects of pre-
analytical variables on core AD CSF biomarker concentration based on a systematic 
literature review.  
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3. Methods 
In accordance with PRISMA guidelines, we conducted a systematic review of the 
PubMed (comprising citations from MEDLINE, life science journals and online books) 
and Cochrane Library databases from 1995 to March 2017 with five sets of search 
terms to identify studies that analyzed the effect of pre-analytical variables on AD 
CSF biomarkers. In addition, we examined reference lists of reviews and selected 
original research articles for relevant studies; the authors also suggested additional 
relevant publications. The PubMed search strategy was designed to select studies 
with pre-analytical variables of Aβ(1–42), pTau, or tTau concentration in CSF 
(Appendix A). Duplicates within searches were removed by a reviewer and abstracts 
were screened using predefined criteria:  
 eligible studies described AD CSF biomarker measurements when one or 
more pre-analytical variable(s) were investigated 
 studies were excluded if 1) they did not collect and analyze CSF, 2) did not 
specifically include or mention Aβ(1–42), pTau or tTau, 3) steps 
investigated referred to analytical rather than pre-analytical variables, 4) 
were not in English, 5) were not based on humans, 6) were conference 
abstracts only, or 7) were review articles. 
Studies examining the effect of pre-analytical variables were evaluated and evidence 
that a variable had no effect, or altered concentration, was extracted and 
summarized.  
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4. Results 
4.1. Comparison of pre-analytical protocols for CSF measurements of core AD 
biomarkers 
We identified six pre-analytical protocols used in multicentre, international studies 
including AD biomarker measurements (Table 1). Several steps were different and 
these steps were compared in Table 1. Only the recommended location of sampling 
(LP) and storage temperature was the same in all protocols examined. In contrast, 
recommendations for LP needle size, collection volume, and centrifugation steps 
varied. 
4.2. Summary of pre-analytical variable effects on CSF measurements of core 
AD biomarkers 
The systematic review identified 593 articles; 211 duplicates were removed and 49 
studies were assessed (Fig. 1). The evidence for the influence of CSF sampling 
procedure (Table 2), CSF storage conditions (Table 3) and CSF treatment conditions 
(Table 4) on core AD biomarker concentration (see Fig. 2) are discussed in more 
detail below. 
4.2.1. The influence of sampling procedure on CSF biomarker concentration 
Several variables within the process of taking CSF samples from individuals could 
affect biomarker concentration. These include the conditions immediately prior and 
during the sampling procedure, for example, the timing, method (e.g., needle type) 
and the technique used. 
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4.2.2 Timing of CSF sampling 
Most current protocols recommend a time window to draw CSF for Aβ(1–42) 
measurements (Table 1). Despite this recommendation, not all studies assessed 
describe significant differences in CSF biomarker concentration across a 24-hour 
period [89,90]. There were several reports of significant changes in CSF Aβ(1–42) 
concentration over a number of hours (Table 2). CSF samples collected hourly in 15 
healthy individuals revealed a significant (up to 4-fold) change in Aβ(1–42) levels, 
with increasing concentrations over 36 hours [91]. Huang, et al. (2012) also 
described a longitudinal linear rise in CSF Aβ(1–42) concentration over 36 hours in 
young (18–60 years old) control individuals, in addition to a circadian-like sinusoidal 
pattern. The amplitude of diurnal change in CSF Aβ(1–42) concentration decreased 
with age, while hourly dynamics and linear rise were attenuated in individuals with 
known amyloid deposition [92]. A recent report using pooled data from several sites 
also found significant diurnal variation in Aβ(1–42) levels [93], with a gradual 
increase in concentration in the first 12 hours (up to 200% higher from initial baseline 
draw), which did not return to baseline levels after 24 hours. Samples from indwelling 
catheters used in this study derived from individuals who participated in clinical 
research studies and were given placebo treatment [93]. This study comprised the 
highest sample number examining this variable to date (n = 178). All other studies 
examined had relatively small sample sizes (n = 10–15). 
It is notable that, in these studies, CSF was repeatedly sampled via indwelling 
lumbar sac catheterization. Therefore, the frequency of CSF sampling and aspects 
of the procedural technique may have influenced the interpretation of diurnal 
variation. All groups employing this approach noted a steady increase in CSF Aβ 
levels over the first few hours. Materials in the catheter (e.g., the presence of a 
13 
bacterial filter), sampling frequency and the volume of CSF being withdrawn 
(especially nearer the first part of the sampling period) may have influenced the 
results of studies investigating CSF concentration changes over short periods of time 
[93–96]. Moreover, the initial sampling may leave a hole in the dura mater allowing 
CSF to leak in to the surrounding tissues; this could change the CSF circulation 
dynamics, thereby altering CSF Aβ(1–42) concentration.  
The limited data available on diurnal variability of CSF tTau or pTau did not generally 
reveal any significant diurnal change for tTau [89,90], with a linear increase that was 
reported by Slats, et al. (2012) attributed to a methodological artefact [95]. This same 
study was the only one to report a steady increase in pTau and a circadian-like 
fluctuation (over 24 hours using a cosinor fit, a fluctuation of 2.5 pg/mL for individuals 
with AD and 1.4 pg/mL for the control group was seen, n = 6, P < .005) [95].  
In summary, the evidence for diurnal variability of CSF Aβ(1–42) and pTau 
concentration is inconclusive. However, differences in observed diurnal variability of 
CSF Aβ(1–42) between studies may be dependent on CSF sampling procedure 
(e.g., catheterization), age and/or, the presence of amyloid pathology. More accurate 
assays with increased sensitivity in future may aid the resolution of this open 
question. In addition, it would be useful to compare CSF collected at different time 
points in the same individuals over several weeks.  
4.2.3. Location and volume of CSF sampling 
CSF can be sampled from the lumbar region of the spine or the cerebral 
ventricles/cisternae via a shunt. AD biomarker protocols universally recommended 
sampling to be performed by LP at the level of L3/4 or L4/L5, i.e., a level safely 
below the spinal cord (supported by recent consensus guidelines [97]) (Table 1). 
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Collection volumes in these protocols vary from ≥ 1.5 mL to 20 mL (Table 1). CSF 
biomarkers for other neurodegenerative disease (e.g., α-synuclein as a biomarker in 
Parkinson’s disease) may vary along the rostro-caudal gradient [98,99]. If large 
volumes of CSF are obtained via the lumbar sac, CSF will be in effect drawn from 
more rostral reaches of the spinal canal and so any rostro-caudal gradient in 
biomarker concentration would have implications for interpreting results. However, 
we found limited evidence in the literature that CSF AD biomarker concentrations are 
gradient dependent. No significant change in the concentration of CSF Aβ(1–42) was 
observed along the rostro-caudal gradient, when analyzing concentrations in 
different portions of large CSF volume samples [73,100]. This included a comparison 
of CSF biomarker concentration between four successive 10 mL volumes [73]. 
Volumes larger than 50 mL may lead to a slight increase in Aβ(1–42) concentration 
(though this effect is below 5–10% [Hansson O, unpublished observation]); however, 
such excessive volumes are not relevant in most clinical settings.  
The majority of studies examined in this review also found no significant difference 
between CSF Aβ(1–42) concentration from lumbar or ventricular locations 
[90,101,102]. However, a study of 15 patients with normal pressure hydrocephalus 
(NPH) reported higher concentration of CSF Aβ(1–42) from lumbar versus 
ventricular catheter samples [103]. Conversely, higher pTau concentrations were 
noted in ventricular versus lumbar CSF from patients with NPH, in agreement with 
Djukic, et al. [102]. Similar findings were observed for tTau [90,103].  
Available evidence indicates that there is no significant rostro-caudal effect on CSF 
Aβ(1–42) concentrations with the volumes of CSF collected routinely for biomarker 
samples. Further evidence may be required to determine rostro-caudal gradient 
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changes in tTau and pTau in control populations. The rostro-caudal gradient of the 
AD biomarkers may also depend on the patient’s underlying medical conditions. 
4.2.4. Type of puncture needle 
In this review, we did not identify any studies directly comparing the effect of needle 
type on CSF AD biomarkers, probably due to the technical difficulties in varying this 
factor objectively. However, current protocols all recommend an atraumatic (pen-
point) needle, although with different sized gauges (22, 24 or 25 G; Table 1). A study 
found that conventional needles (compared with atraumatic ones) led to minor serum 
protein contamination of CSF [104], though this may not affect AD CSF biomarker 
concentrations (see section 4.2.6).  
As we have found no evidence of an effect of puncture needle on core AD CSF 
biomarker concentration, the current protocol recommendations of needle type may 
relate more to prevention of patient side effects. For example, in multicentre studies, 
atraumatic needles prevented post-LP complaints such as back pain and headache. 
A larger needle diameter was associated with severe headache [105], whereas 
smaller 24 gauge Sprotte needles were associated with a low incidence of post-LP 
headache [106].  
4.2.5. Collection method 
Most current protocols do not specify a drainage method, though the Alzheimer’s 
Disease Neuroimaging Initiative (ADNI) and BioFINDER protocols recommend 
gravity drip to allow CSF to flow freely (Table 1). It is well recognized that different 
tube materials can significantly affect CSF AD biomarker concentration (see below), 
which led to a suggestion that aspirating CSF in plastic syringes could cause a 
significant decrease in Aβ(1–42) concentration compared with gravity drip. 
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Conversely, use of a syringe could enable faster collections and direct aliquoting, 
which could help minimize CSF Aβ(1–42) loss through adsorption. A direct 
comparison of the two methods in a cohort of 54 study participants (38 healthy 
controls, eight with MCI and eight with AD) found no significant differences in CSF 
Aβ(1–42), pTau, or tTau concentration [107]. In this study, aspiration samples were 
taken following sequential gravity drip samples, and so could retain possible gradient 
effects on concentration.  
CSF may also be collected through a catheter (first used to measure the CSF 
pressure), and a comparison of two catheter types found no difference in CSF Aβ(1–
42) concentration [73]. Another study found that manometer use significantly 
reduced (by 4–6%) CSF Aβ(1–38), Aβ(1–40) and Aβ(1–42) concentrations [108]. As 
mentioned, this may be a result of tube or pipette material adsorption (see section 
4.2.1). Overall, there are few studies that have directly compared drainage methods 
and no conclusive evidence of an effect of collection method on core CSF AD 
biomarker concentration has been reported. It would be very challenging to directly 
compare this parameter in more detail without potential confounders. 
4.2.6. Blood contamination 
Blood contamination of CSF from tissue trauma has been reported to occur in ~15% 
of LPs [109], but is most often minor (Blennow K, personal observation). Proteins, 
including albumin and proteases present in blood, may bind or degrade Aβ(1–42), 
[110,111], while blood cells themselves contain significant amounts of Aβ(1–42) 
[112]. Many of these proteins are naturally occurring in the CSF and may be even 
more abundant if the blood-CSF barrier is impaired (e.g., with acute meningitis) or 
when the CSF samples are contaminated with blood during the collection process. 
Accordingly, CSF collection protocols consistently recommend discarding the initial 
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1–2 mL of CSF if blood contamination is noted based on visual assessment, or if the 
CSF sample contains > 50 erythrocytes per μL (Table 1). However, there is 
conflicting evidence on whether plasma proteins can affect biomarker concentration. 
For example, two studies found no significant effect of the addition of albumin at the 
time of sample incubation [113] or minimal blood contamination [73] on Aβ(1–42) 
concentration. Conversely, CSF Aβ(1–42) concentration in samples spiked with 
plasma (corresponding to a CSF/serum albumin ratio of 55; Table 2) was 
significantly reduced up to 49% [73]. It should be noted that CSF/serum albumin 
ratios in this range are not found in AD cases or other chronic neurodegenerative 
disorders. The opposite effect was seen by Leitao, et al. (2015), who spiked samples 
with 5000 erythrocytes/µL and found a small but significant increase in both CSF 
Aβ(1–42) and pTau concentration (6 and 11%, respectively) [114]. Experimental 
design may therefore explain some of these conflicting results. Red blood cell 
contamination may be more critical for the concentration of biomarkers for other 
neurological conditions, such as Parkinson’s disease, than the core AD biomarkers 
[115,116]. 
Taken together, these studies suggest that blood contamination may affect core AD 
biomarker concentration and that grossly contaminated samples should be 
discarded. However, further research may be needed to determine acceptable 
contamination levels. 
4.3. The influence of CSF storage on biomarker concentration  
The steps between performing a LP and measuring CSF biomarker concentration 
may introduce variability. These include the types and size of pipettes and tubes for 
transferring and processing samples, the CSF volume-to-surface ratio, and the 
temperature at which samples are held.  
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4.3.1. Tube material 
Many published studies examined tube material and the majority showed that 
different tubes adsorb CSF biomarkers to varying degrees. CSF samples are often 
exposed to many tubes, not only collection and storage tubes, but also those used 
for pooling CSF for certain purposes. Of the three CSF AD biomarkers examined in 
this review, Aβ(1–42) concentration was affected to the greatest extent, likely due to 
the hydrophobic nature of the peptide.  
The change in CSF biomarker concentration caused by the tube material, or ‘tube 
effect’, was shown to happen quickly (< 5 minutes) and was not further affected by 
long incubation time (up to 48 hours, at 2–8°C [117]). The ‘tube effect’ on CSF Aβ(1–
42) concentration loss was greater when the initial CSF Aβ(1–42) concentration was 
higher (>1000 pg/mL compared with 400–500 pg/mL [83]). 
Standard protocols recommend polypropylene (PP) as a tube material (Table 1); 
indeed, polystyrene and glass tubes significantly reduced CSF Aβ(1–42) 
concentration [73,118,119]. However, recent groups have shown that the type of PP 
- as homo or copolymers - or with additives such as polyethylene copolymers, also 
significantly altered CSF Aβ(1–42) concentration [117,120–122]. For example, 
variation of up to 48% was observed among 11 tubes all listed by their manufacturer 
as PP [117].  
Tubes treated to be ‘low binding’ (LoB) were found to yield significantly greater CSF 
Aβ(1–42) concentration compared with untreated PP tubes [123,124]. Moreover, the 
chemical composition of the tube could influence the effects of freezing and tube 
volume on CSF Aβ(1–42) concentration; for example, an additional freeze/thaw cycle 
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reduced CSF Aβ(1–42) concentration by > 25% in a PP tube, but had almost no 
effect when LoB storage tubes were used [124]. 
CSF Aβ(1–42) adsorption onto tube surfaces will occur with each transfer to a new 
tube [83,124,125]. Reduced recovery of measurable CSF Aβ(1–42) can result from 
adsorption to transfer pipettes, in addition to collection or storage tubes [83]. In one 
study, transfer of CSF samples from LoB tubes to PP tubes decreased Aβ(1–42) 
concentration by 42.5%. This is significant since a recent survey across four 
academic AD diagnostic reference centres found that 0–2 transfers of CSF occur on 
average (occasionally more) [83].  
Different tube types have been shown to influence CSF pTau and tTau 
concentration, but within the range of acceptable assay variation (± 8%, [117]). 
Although one study found that CSF tau concentration was not affected by adsorption 
when transferred between different brands of tubes [83] another recent study did find 
transfer to a PP tube caused a significant decrease in CSF tTau [126], while a 
reduction was also reported for transfers to polystyrene tubes [119].  
In summary, the evidence indicates that CSF Aβ(1–42) concentration is significantly 
affected by tube type, while CSF pTau and tTau concentration is not notably 
affected. Peptide ratios can be more consistent than single peptide concentrations 
as they are not altered as much by interactions of single peptides with tube material 
[119]. Interestingly, it has been shown that using Aβ(1–42)/ (1–40) ratios [83,119], 
but not Aβ(1–42)/tau [126], can reliably compensate for tube-based variation in 
Aβ(1–42) concentration.  
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4.3.2. Aliquot tube volume 
Current protocol recommendations for both tube volume (between 0.1–0.75 mL) and 
the CSF fill volume (either no specification, or between 50 and > 75% full) vary 
considerably (Table 1). 
The CSF surface to tube volume ratio can affect CSF Aβ(1–42) concentration; there 
is a consensus in the literature that a larger ratio results in lower CSF Aβ(1–42) 
concentration (Table 3; [83,114,124,127]). For example, one study observed that a 
loss in CSF Aβ(1–42) concentration following tube transfer depended on starting 
volume, with higher surface area to volume ratios increasing Aβ(1–42) adsorption 
[83]. In contrast, there is limited evidence of an effect of tube volume on CSF tTau 
concentration, although a decrease in concentration with decreased volume, 
dependent on tube material, was reported for tTau [124] and a weak association also 
noted [127]. We found no reports of an effect of tube volume on the concentration of 
pTau. Current evidence supports limiting the surface area to volume ratio when 
using samples for CSF Aβ(1–42) concentration, but specifics vary, warranting further 
investigation.  
4.3.3. Temperature between collection and analysis/storage 
There are several differences in the recommended time that CSF samples can be 
left at room temperature (RT) or cooled (Table 1). Many studies have investigated 
the stability of CSF biomarkers at different temperatures, with emphasis on the 
length of time samples were left at RT immediately following LP as a practical 
consideration in the clinical setting (Table 3).  
Several studies that started with fresh samples agreed that storing CSF at RT for up 
to 24 hours had no significant effect on CSF Aβ(1–42) concentration [73,100,128]. 
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Measurements on samples left at RT for longer than 24 hours have been more 
variable, with studies reporting increasing [100,129] or decreasing [130] CSF Aβ(1–
42) concentration, or no effect [131–133]. Hypotheses for the increase or decrease 
include Aβ(1–42) release from amyloid-binding proteins [100], increased Aβ(1–42) 
adsorption to tube material [83], or proteolytic degradation [129]. 
In comparison with CSF Aβ(1–42), studies report no changes in CSF pTau or tTau 
concentration over short timeframes when kept at RT [128,129,131,134]. A decrease 
in tTau protein at 37°C or RT has been reported after ~12 days, though this was not 
seen in samples kept at 4°C [130,132].  
A few studies have assessed the influence of different cooling methods or freezer 
temperatures, with limited evidence that colder temperature may limit biomarker 
concentration loss. For example, snap freezing samples in liquid N2 increased CSF 
Aβ(1–42) concentration compared with freezing in a -80°C freezer (P = .048), but 
may not be practical in the clinic setting. In addition, freezing at -80°C yielded a 
higher CSF pTau concentration than freezing at -20°C (P = .001) [100].  
Most evidence for CSF Aβ(1–42) concentration supports limiting the time at RT to 
less than 24 hours, followed by analysis or freezing. However, a comparison using 
newer fully automated assays with fresh CSF stored for various times compared with 
samples frozen at -20°C or -80°C for the same period is warranted. Although no 
evidence of significant temperature effect was found for tTau and pTau, freezing 
method and temperature effects on tau concentrations also merits further study. 
4.3.4. Freeze/thaw cycles 
Evidence on the effects of freeze/thaw cycles on biomarker concentration is 
inconsistent; however, up to three cycles was the standard recommendation in 
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current protocols (Table 1). Following many reports on freezing effects on CSF 
biomarker concentration, most studies have shown that multiple freeze/thaw cycles 
decrease CSF biomarker concentration. The majority of studies found no significant 
effect of one freeze/thaw cycle on the CSF concentration of Aβ(1–42), pTau or tTau, 
compared with fresh samples (Table 3), or on mass spectra intensities [135]. One 
notable exception was a multicentre analysis that suggested frozen samples had 
higher diagnostic accuracy than fresh samples for CSF tTau and Aβ(1–42) 
concentration [29], although this has not been confirmed. 
Significant reductions or unsystematic changes in CSF Aβ(1–42) concentration have 
been described after strict application of two [113,120], three [130,131,136], four 
[100] or five [114] cycles of freeze/thawing. A freeze/thaw-dependent decrease in 
CSF Aβ (1–42) concentration may be more pronounced at lower initial 
concentrations of CSF Aβ (1–42) [113].  
For CSF pTau and tTau, similar disagreement exists regarding the number of 
freeze/thaw cycles that are possible before concentration is significantly reduced. 
For example, no group has described a significant change in concentration from one 
freeze/thaw cycle, though a significant reduction was seen in CSF tTau 
concentration after two [100] or three [131,132] cycles. Conversely, Leitao, et al. 
(2015) found up to at least five freeze/thaw cycles had no significant effect on CSF 
tTau or pTau concentration.  
In summary, studies agreed that increasing the number of freeze/thaw cycles 
decreases CSF concentration of Aβ(1–42), tTau and pTau, but evidence on the 
exact number of cycles is inconclusive. A note of caution is recommended when 
assessing this variable, however; the influence of freeze/thaw cycles reported here 
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may not be purely a result of the temperature change, but rather due to the pipetting 
and tube transfer steps or a change in surface area/volume ratio increasing 
adsorption to these materials.  
4.3.5. Storage duration 
Current protocols do not specify a time limit on long-term storage at -80°C, except 
the < 2 years recommended in the BIOMARKAPD protocol [80] (Table 1). 
Investigations have consistently shown that CSF biomarkers (Aβ(1–42), pTau and 
tTau) are reasonably stable over time, when stored at -80°C (Table 3; 
[73,123,130,131,133,134,137–140]); a recent study found that, if using a single 
batch of assays following varying sample storage times, storage for up to 12 years 
had no significant effect [140]. Only one report was found in this review that deviated 
from this, describing an increase in concentration of some samples following 7 
months [138]. However, it should also be noted that lot-to-lot variability or assay 
storage may have an influence when comparing CSF concentration changes 
analyzed on different occasions over time [140].  
In general, the literature is in agreement that storage at -80°C for up to 6 months has 
little or no effect on CSF Aβ(1–42), pTau181P, and tTau concentration. 
4.4 The influence of CSF treatment on biomarker concentration 
The treatment of CSF prior to biomarker assessment can affect biomarker 
concentration. This includes additives, heat treatment, centrifugation, and/or mixing 
of samples.  
4.4.1 Additives 
Additives are not recommended by current diagnostic protocols (Table 1). Additives 
such as mild detergents (Triton-X 100 or Tween-20) can alter protein binding, and 
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several studies have shown that CSF samples that have been treated with~0.05% 
Tween-20 have higher CSF Aβ(1–42) concentration (Table 4). For example, 0.1% 
Tween-20 or 0.05% TritonX-100 both increased CSF Aβ(1–42) concentration by 
~75% in individuals with AD [73], although Willemse, et al. (2017) found that the 
addition of Tween-20 did not improve the discrimination of AD patients from control 
subjects [83]. 
The detergent possibly interferes with binding of CSF Aβ(1–42) to tube material 
[122,127], and therefore could be a way of mitigating adsorption [123]. 
Subsequently, the standard strong correlation between tube surface area and 
increased CSF Aβ(1–42) concentration, probably reflecting Aβ(1–42) adsorption, is 
not present in samples containing 0.05% Tween-20 [127]. Even a pre-wash step of 
tubes with detergent-containing buffers was enough to considerably reduce CSF 
Aβ(1–42) tube adsorption (optimal dose recovery was 0.01% Tween-20) [124]. To 
prevent Aβ(1–42) loss in earlier steps in pipette tips or tubes prior to transfer, 
detergent could be added at the time of CSF withdrawal [83]. 
Detergents or other additives could affect the concentration and detection of other 
analytes used as biomarkers and modify the equilibrium between protein-bound and 
free analytes in CSF, or the ratio of Aβ isoforms, and so should be used with caution 
[124]. In addition, detergents could affect reagent antibodies in immunoassays. 
Despite this, 0.05% detergent (Triton-X 100 or Tween-20) did not seem to affect 
sensitivity, specificity, diagnostic accuracy [141] or intra-assay variability for CSF 
Aβ(1–42) concentration [124]. Some authors do explicitly recommend detergent use 
to mitigate CSF Aβ(1–42) adsorption [123,127], for example, for older samples 
stored in high absorption tubes. 
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In summary, there is evidence that 0.05% Tween-20 may help mitigate CSF Aβ(1–
42) adsorption onto tubes and boost concentration [124,127,141,142]. Though there 
is limited evidence that 0.05% detergent has any effect on CSF tTau or pTau 
[141,142], unknown effects on potential interactions of additives with other proteins 
and assay reagents understandably restricts any recommendation for their use. It 
should also be noted that the certified reference material for Aβ(1–42) is composed 
of neat CSF without additive, calibrated against mass spectrometry methods [75]. It 
would be interesting to directly compare CSF Aβ(1–42) concentration between the 
lowest binding tubes on the market with and without the addition of 0.05% Tween-20 
to quantify potential loss in more detail. 
4.4.2 Heat denaturation 
Current protocols do not recommend heat denaturation as a protocol step prior to 
CSF biomarker measurement (Table 1). Nevertheless, the possible effect of this step 
on CSF Aβ(1–42) concentration has been sporadically investigated (Table 4). In 
2000, Vanderstichele et al demonstrated that boiling CSF samples had no effect on 
CSF Aβ(1–42) concentration [113]. In contrast, heat denaturation was recently 
reported to increase CSF Aβ(1–42) concentration (15 mins at 100°C increased levels 
by 42–71%), and this increase was hypothesized to be due to detection of Aβ(1–42) 
that was previously bound in protein complexes or masked by epitopes [73]. The 
evidence is inconclusive about the effect of heat treatment on CSF biomarkers; 
however, a heating step is unlikely to occur in or be recommended for routine clinical 
use. 
4.4.3 Centrifugation 
Centrifugation has been investigated often and is recommended in several standard 
protocols, particularly with haemorrhagic CSF samples (Table 1). However, results 
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remain inconsistent (Table 4). Significant reductions in CSF Aβ(1–42) concentration 
following centrifugation have been reported [73,141,143], possibly reflecting 
increased adhesion of Aβ(1–42) to the cell walls, or precipitation of lysed cells during 
the process. 
Leitao, et al. (2015) found no effect of different centrifugation speeds on CSF Aβ(1–
42), tTau or pTau concentration except when total protein levels were high [114]. No 
significant differences were reported in CSF tTau or pTau concentration from 
including or omitting a centrifugation step [100,114,130,141]. Centrifugation may be 
required if samples contain some blood contamination (4.1.5 Blood contamination), 
and if so the step may reduce CSF Aβ(1–42) but not tTau or pTau concentration 
(Table 4). The potential reduction in Aβ(1–42) must be taken into consideration, and 
we conclude centrifugation effects need further quantification if it is to be used 
sporadically to mitigate blood contamination.  
4.4.4 Shaking 
The effect of shaking on CSF biomarker concentration has not been extensively 
examined and is not listed in current protocols (Table 1). Shaking CSF samples for 
48 hours at RT led to a small but significant decrease in median Aβ(1–42) 
concentration of 7% (n = 20, P < .05) and tTau of 30% (n = 20, P < .001; [144]). 
Conversely, excessive vortexing did not have any effect on CSF Aβ(1–42) 
concentration in a recent report [83]. Sample mixing may be more important if 
samples have been frozen and then thawed (Hansson O., personal observation). 
The benefits of creating more homogeneous samples by shaking or mixing, 
especially following freezing steps, requires further study. 
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4.5 Additional variables 
During this review process, a small number of potential pre-analytical variables were 
uncovered that have not received much consideration to date. This includes steps 
contained in current protocols without extensive investigation (for example, whether 
fasting before the CSF collection procedure is necessary), and also steps not 
included in current protocols for which some evidence indicates an influence on CSF 
biomarker concentration. The latter includes bacterial growth conditions, where 
bacterial contamination significantly reduced levels of Aβ(1–42) and diminished tau 
concentration [144]. However, this could be alleviated by preventing bacterial growth 
with 0.1% sodium azide – which did not alter starting concentrations even after 5 
days at RT [133]. In addition, tube sterilization methods can significantly increase 
their adsorbance properties (e.g., irradiation significantly increased the adsorbance 
properties of homopolymer tubes [121]). Further analysis into these potential 
variables may be required. 
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5. Discussion 
5.1. Conclusions and recommendations 
The range of pre-analytical protocols used has introduced the potential for significant 
variability in CSF AD biomarker measurements. In this review, we summarized the 
current body of evidence and highlighted the most important key pre-analytical 
variable steps to consider in the future, such as tube material, the length of time 
samples are kept at RT before storage or analysis, and the relationship of tube 
surface area to sample volume (Fig. 2). In particular, CSF Aβ(1–42) concentration is 
significantly affected by tube type, with potentially important consequences for 
clinical and research evaluation. More consistent sample processing and a 
consensus on LoBind tube choice would help the field. In the future, it is also 
recommended that a better tube, capable of inhibiting CSF biomarker adsorption, be 
developed and adopted.   
Although there are differences in the variables that specifically affect CSF Aβ(1–42), 
tTau, and pTau, we found that generalizations could be made across these three 
biomarkers. In particular, our results showed that the variables (in addition to tube 
material) with the largest amount of conflicting data were: temperature between 
collection and analysis/storage, the number of freeze/thaw cycles advised, 
centrifugation and additives. In contrast, steps for which either little variability exists 
or where there is some consensus regarding parameters that should be followed 
were: CSF collection steps and storage time (although the effect of storage 
temperature and duration should be studied using new, high-precision assays). A 
number of pre-analytical variables may require further research, for example tube 
volume and shaking (Fig. 2).  
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One limitation of this review may be that some unstudied variables or interactions of 
variables may yet have a significant influence on biomarker concentration. Further 
comprehensive research with more robust and precise assays will hopefully shed 
light on this. The wide variety in methodology in the research studies included in this 
review, where most studies did not combine several variables or measure several 
biomarkers in the same experiments, may make some comparisons weaker. In 
addition, this review was limited to analyzing evidence for pre-analytical variables 
affecting the concentration of CSF Aβ(1–42), tTau, and pTau. Other biomarkers for 
AD have been suggested, alone or in combination, for example Aβ(1–38), Aβ(1–40), 
sAPPα, sAPPβ, ApoE, neurofilament light, neurogranin, YKL-40 and VILIP-1 
[39,145-147], and there is an emerging body of evidence for potential CSF 
biomarkers of other neurodegenerative disorders [148,149].  
We recommend that a universal pre-analytical protocol for CSF handling be 
developed and incorporated into future clinical trials, registries, and routine AD 
diagnosis. This protocol should attempt to control for the variables identified in this 
review as having the most influence on biomarker concentration. Aβ(1–42) appeared 
to be the most affected by the pre-analytical variables evaluated; however, a 
universal protocol would reduce variability of all CSF biomarkers. This protocol could 
reflect the latest evidence on potentially important pre-analytical variables, while 
ideally being easy to implement and practical for clinical settings. Although clinical 
and analytical variables will still have an influence, a universal pre-analytical protocol 
will help enable accurate comparison of results between studies and further limit 
potential diagnostic variability. 
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Supplementary materials 
Appendix A 
Search terms used in PubMed literature search: 
Search  
1 ((pre-analytic* OR pre-analytic*) AND (CSF OR cerebrospinal fluid) AND 
("1995"[Date - Publication] : "3000"[Date - Publication])  
2 (variab* AND (CSF OR cerebrospinal fluid) AND (amyloid beta 42 OR 
amyloid-β 42 OR Aβ42 OR Abeta42) AND ("1995"[Date - Publication] : 
"3000"[Date - Publication])  
3 variab* AND (CSF OR cerebrospinal fluid) AND (phosphorylated tau OR 
ptau OR p-tau OR phospho tau OR phospho-tau) AND ("1995"[PDAT] : 
"3000"[PDAT])  
4 (variab* AND (CSF OR cerebrospinal fluid) AND (total tau OR ttau OR t-
tau OR totaltau OR total-tau) AND ("1995"[Date - Publication] : 
"3000"[Date - Publication])  
5 validation AND (CSF OR cerebrospinal fluid) AND biomarker* AND 
(alzheimer's OR alzheimer OR AD) AND (amyloid beta 42 OR amyloid-β 
42 OR Aβ42 OR Abeta42 OR phosphorylated tau OR ptau OR p-tau OR 
phospho tau OR phospho-tau OR total tau OR ttau OR t-tau OR totaltau 
OR total-tau) AND ("1995"[Date - Publication] : "3000"[Date - 
Publication]) 
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Tables/Figures 
 
Fig. 1. PRISMA flow diagram of literature search and study selection flow for 
systematic reviews. 
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Fig. 2. Pre-analytical variables in CSF biomarker analysis.  
Abbreviations: Aβ, β amyloid; CSF, cerebrospinal fluid
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Table 1  
Comparison of existing protocols used for pre-analytical handling of CSF samples before measuring concentrations of core AD 
biomarkers 
 ADNI  
[150][151] [29] 
BioFINDER 
[14,35]* 
BIOMARKAPD  
[80] 
AA 
[152] 
  
ABSI  
[71] 
Standard 
Biobanking 
Protocol [85] 
Fasting before 
LP 
Minimum 6 h  Not required Not required Not required Not required Not mentioned 
Timing of CSF 
sampling 
Morning Standardized 
(0800–1200 h) 
Day time 0800–1200 h Any time Standardized 
within each 
centre 
Location of 
sampling (LP) 
L3–L5 L3–L5 L3–L5 L3–L5 L3–L5 L3–L5 
Type of LP 
needle 
22G and 24G 
atraumatic 
22G atraumatic 25G atraumatic 22G, atraumatic 22G, atraumatic Atraumatic 
60 
Collection 
method 
Gravity drip 
(22G, 
recommended) 
or suction (24G)  
Gravity drip Not specified Not specified Not specified Not specified 
Tube type PP (Sarstedt) PP PP PP PP – 
standardized 
small volume 
PP, screw cap 
Collection 
volume (mL) 
15–20 10 x 2, gentle 
mix 
12 10–12, gentle 
mix 
≥1.5 12 
Temperature 
between 
collection and 
analysis/storage 
One transfer (for 
shipping), dry 
ice 
RT < 30 mins, 
freeze and ship 
on dry ice if 
longer 
< 5 days, 4°C RT < 2 days RT < 5 days RT, 30–60 mins 
(max 2 hours), 
ship on dry ice 
Blood 
contamination  
Should be clear 
CSF only; 
discard initial 1–
Discard initial  
1–2 mL if bloody 
< 50 
erythrocytes/µL 
CSF (for 
Should be clear 
CSF only; 
discard initial 
< 50 
erythrocytes/µL 
CSF. Discard 
< 50 
erythrocytes/µL 
CSF 
61 
2 mL (or more if 
needed) 
biomarkers 
highly abundant 
in peripheral 
blood) 
0.5–1 mL (or 
more if needed) 
initial 1–2mL if 
bloody 
Centrifugation No [151];  
yes 2000 x g 10 
mins 4°C [29] 
Yes– 2000 x g 
10 mins RT 
Yes – 2000 x g 
10 mins RT 
Yes No (unless 
visually 
haemorrhagic; 
2000 x g 10 
mins RT) 
Yes – 2000 x g 
10 mins RT 
Freezing 
temperature 
(°C) 
-80°C (following 
dry ice) 
-80°C -80°C -80°C -80°C -80°C 
Aliquots                   
Volume (mL) 
       
 
 
0.5 [29] 
 
 
 
≤ 1 
 
 
 
0.25–0.5 tubes 
 
 
 
1 
 
 
 
small 
 
 
0.1–0.75 
aliquots in 1–
2mL tubes 
 
62 
Fill level (%) Not specified ≥ 50 > 75 Not specified ≥ 50 75 
Freeze/thaw 
cycles (n) 
≤ 2 1 ≤ 2 1 ≤ 2 1 
Storage time 
(years) 
Not specified Not specified ≤ 2 Not specified ≤ 2 Not specified 
*Hansson O, personal communication. 
Abbreviations: AA, Alzheimer’s Association; ABSI, Alzheimer’s Biomarkers Standardization Initiative; ADNI, Alzheimer’s Disease 
Neuroimaging Initiative; CSF, cerebrospinal fluid; LP, lumbar puncture; PP, polypropylene; RT, room temperature. 
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Table 2  
The influence of LP on CSF core AD biomarker concentration  
Pre-
analytical 
variable 
Aβ(1–42) tTau pTau 
Evidence of 
influence of 
variable 
Evidence of no 
influence of 
variable 
Evidence of 
influence of 
variable 
Evidence of no 
influence of 
variable 
Evidence of 
influence of 
variable 
Evidence of no 
influence of 
variable 
Timing of 
CSF 
sampling 
1.5–4-fold 
change [91], 
slight but 
significant 
↓9.3% after 
~5 hours, return 
after 24 hours 
[73]; low 
No significant 
effect [89,90], 
CV 5.5% [89] 
 
 
 
Linear ↑ over 36 
hours in AD 
patients only 
[95] 
No significant 
effect [89,90,95], 
CV 8.2% [89] 
 
Linear ↑ over 
36 hours in AD 
patients only 
and significant 
fluctuation 
pattern in both 
AD patients and 
controls [95] 
No significant 
effect [90], not 
significant, CV 
11.9 % [89] 
 
64 
circadian-like 
fluctuation up to 
1.7-fold change 
[95], up to 200% 
increase in 
indwelling 
catheter studies 
[93]; ↑ over time 
in younger 
participants [92] 
 
 
Location and 
volume of 
CSF 
sampling 
↑ in lumbar vs 
ventricular in 
NPH patients 
[103] 
No significant 
effect 
[73,90,100,102] 
↑ concentration 
from ventricular 
vs lumbar 
catheter [90]; in 
NPH patients 
[103] 
No significant 
effect [100,102] 
↑ concentration 
in ventricular vs 
lumbar fraction 
in NPH patients 
[102,103] 
No significant 
effect [100] 
 
65 
Type of 
puncture 
needle 
None reported None reported None reported 
Collection 
method 
Use of a 
styrene-
butadiene 
copolymer 
manometer 
caused sig 
↓4.3% 
(± 2.4 SE,  
P = .047; [108]) 
No difference in 
catheter type 
[73]; no 
difference 
between gravity 
drip or aspiration 
(n = 44; [107]) 
None reported No difference 
between gravity 
drip or aspiration 
(n = 44; [107]) 
None reported No difference 
between gravity 
drip or aspiration 
(n = 44; [107]) 
Blood 
contamination 
Plasma 
contamination of 
CSF/albumin 
ratio of 55 ↓ 
No significant 
effect: up to 
5000 per µl [73], 
up to 10% 
None reported No significant 
effect [114] 
 
Blood spiked 
samples 
5000 per µl 
None reported 
66 
concentration by 
up to 49% [73]; 
blood spiked 
samples 5000 
per µl ↑6% 
(P < .05; [114]) 
contamination 
by haemolysed 
blood [123]. No 
effect of albumin 
[113] 
↑11% (P < .05; 
[114]) 
 
Abbreviations: Aβ, β amyloid; AD, Alzheimer’s Disease; CSF, cerebrospinal fluid; CV, coefficient of variation; LP, lumbar puncture; 
NPH, normal pressure hydrocephalus; pTau, phosphorylated tau; SE, standard error; tTau, total tau  
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Table 3 
The influence of CSF storage on core AD biomarker concentration  
Pre-analytical 
variable 
Aβ(1–42) tTau pTau 
Evidence of 
influence of 
variable 
Evidence of no 
influence of 
variable 
Evidence of 
influence of 
variable 
Evidence of no 
influence of 
variable 
Evidence of 
influence of 
variable 
Evidence of no 
influence of 
variable 
Tube material Significant ↓ 
polystyrene 
storage versus 
PP (mean 19%,  
P = .002, [73], 
mean 36% ↓ 
polystyrene, 
[118]) or 
polystyrene 
No significant 
difference 
between tube 
brands [83]; no 
significant 
difference 
between PP 
and glass [73]; 
PP no 
Significant 
differences from 
different types 
of PP tube 
(acceptable 
range; [117]); 
Significant ↓ in 
PS compared 
with other tubes 
No significant 
effect [117]; No 
significant 
difference 
between tube 
brands [83] 
 
Significant 
differences from 
different types 
of PP tube 
(acceptable 
range; [117] 
 
No significant 
effect ; No 
significant 
difference 
between tube 
brands [83] 
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versus PP, PC 
or PX (P < .001, 
[119]) or ↓ when 
stored in glass 
PP (mean 33%, 
P < .001 [118]); 
Significant 
differences from 
different types 
of PP tube 
[117,120,122]; 
copolymer and 
Sarstedt tubes 
significant ↓ 
versus 
homopolymer ; 
significant effect 
[118]; LoB no 
significant effect 
when tested 
after one 
freeze/thaw 
[123] 
 
(P < .001 [119]; 
decrease when 
transferred to 
PP from LoB 
tube [126] 
69 
much higher 
concentration in 
Sarstedt PP 
[117]; 
Significant ↓ in 
PP versus LoB 
tubes (11.0%; 
[124]); 
Significant ↓ in 
Nunc PP 
cryotubes 
compared with 
LoB [123] 
70 
Aliquot tube 
volume 
↓ volume from 
75 to 50% = 
↓3.7% (P = .03; 
[114]); ↑ volume 
x 30 = ↑ of ~2-
fold [127]; ↑ 
surface 
area/volume 
ratio = ↓ [83], in 
PP [124]  
None reported ↓ volume PP 
tubes 1.5mL to 
0.5mL = ↓ 4.5% 
(P = .001 [126]) 
No significant 
effect [114,127] 
None reported No significant 
effect [114] 
 
Temperature 
between 
collection and 
analysis/storage 
2 days RT or 
4°C ↓ ~20% 
[130]; 2 days 
RT ↑ ~15% 
[100]; 
Up to 24 hours 
RT = no 
significant effect 
[73,100,128]; up 
to 6 hours RT or 
3 days 4°C also 
↓ after holding 
at -20°C 
compared 
with -80°C 
[100]; ↓after ~12 
days at 37°C 
No difference 
up to 22 days at 
4°C or 18°C 
[130]; 24 hours 
RT [128,134]; 7 
days RT [131]; 
↓ after freezing 
at -20°C 
versus -80° 
(P = .001 [100]) 
 
No effect 
24 hours at RT 
[128,129,134];  
up to 3 days 
[54]; 7 days RT 
[131]; up to 5–
71 
↑ after 24 hours 
RT [129]; 
significant 
changes in 
peptide patterns 
(mass spec) 
after 24 hours 
RT [135]; ↓ after 
14 days -20°C 
[132] 
had no effect on 
CSF mass 
spectra [135]; 
7 days RT 
[131]; 14 days 
RT or 4°C [132]; 
up to 5–7 days 
routine storage 
conditions [133] 
[130]; ↓ after 
14 days RT 
[132] 
no significant 
effect 14 days 
at -20°C or 4°C 
[132] up to 5–7 
days routine 
storage 
conditions [133] 
 
7 days routine 
storage 
conditions [133]; 
14 days RT, 
4°C or -20°C 
[132] 
Freeze/thaw 
cycles 
Two cycles ↓ 
[113]; ↓ 17.6% 
(P < .001; 
[120]); three 
cycles ↓~30% 
One 
freeze/thaw = 
no difference 
[73,120,130,153
] or on mass 
spectrometry 
Significant ↓ 
> 2 cycles [100]; 
significant ↓ 
17% ≥3 cycles 
[132] 
 
One 
freeze/thaw = 
no difference 
[130,153]; up to 
three [131]; up 
Significant ↓ 
16% ≥ 3 cycles 
[132] 
Up to three 
[131]; up to four 
[100]; up to five 
[114] 
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[136], ↓~20% 
[130]; 
four cycles 
↓16% (P < .05; 
[100]); five 
cycles ↓5% (P 
< .05; [114] 
intensities ; up 
to three 
[100,123,131] 
[132][114] 
to five [114]; up 
to six [130] 
Storage time 
(-80°C) 
↑ after 7 months 
[138] 
 
> 3 months 
[123]; up to ~1 
year [133,137]; 
2 years 
[73,131]; 
prolonged 
storage 
[130,138-140]; 
None reported > 1 year -70°C 
no effect [134]; 
prolonged 
storage does 
not have an 
effect 
[130,131,139,14
0,154]  
None reported >1 year -70°C 
no effect [134]; 
prolonged 
storage does 
not have an 
effect 
[131,140,154]  
73 
up to 7 months 
[138] 
 
Abbreviations: Aβ, β amyloid; AD, Alzheimer’s Disease; CSF, cerebrospinal fluid; LoB, low binding; PC, polycarbonate; PP, 
polypropylene; PS, polystyrene; pTau, phosphorylated tau; PX, a copolymer of polystyrene and acrylonitrile; RT, room temperature; 
SE, standard error; tTau, total tau. 
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Table 4 
The influence of CSF treatment on biomarker concentration 
Pre-analytical 
variable 
Aβ(1–42) tTau pTau 
Evidence of 
influence of 
variable 
Evidence of no 
influence of 
variable 
Evidence of 
influence of 
variable 
Evidence of no 
influence of 
variable 
Evidence of 
influence of 
variable 
Evidence of no 
influence of 
variable 
Additives 0.05% Tween-
20 = ↑ of ~29% 
(control and 
MCI) to 35.9% 
(AD), P < .001 
[141], ↑ of 69%,  
P < .001 [142]; 
↑ 
No significant 
effect on 
concentration of 
up to 0.05% 
Tween-20 or 
Triton X-100 
[124]; no effect of 
0.1% NaN3 on 
0.05% Tween-
20 = ↑ of 4%, P 
= .001 [141] 
 
Any observed 
changes not 
significant 
reported [142] 
None reported Any observed 
changes not 
significant [141] 
[142] 
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[73,122,123,127
,136,138] 
concentration 5 
days RT [133] 
Heat 
denaturation 
↑ [73]; 
SDS heat 
prevented a ↓ 
otherwise seen 
following 
freezing, with 
SDS [155] 
No significant 
effect [113] 
None reported None reported 
Centrifugation ↓ [73,141,143] No significant 
effect 
[100,114,130] 
↓ [143] 
 
No significant 
effect 
[100,114,130,14
1] 
↓ [143] No significant 
effect 
[100,114,130] 
Shaking ↓ 7% 48 hours 
RT  
(P < .05; [144] 
No effect of 
vortexing [83] 
↓ 30% 48 hours 
RT  
(P <. 001; [144]) 
None reported None reported 
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Abbreviations: Aβ, β amyloid; AD, Alzheimer’s Disease; CSF, cerebrospinal fluid; MCI, mild cognitive impairment; NaN3, sodium 
azide; pTau, phosphorylated tau; RT, room temperature; SDS, sodium dodecyl sulphate tTau, total tau. 
 
